|
|
| | N-(5-AMINO-5-CARBOXYPENTYL)-ACETAMIDINE Basic information |
| Product Name: | N-(5-AMINO-5-CARBOXYPENTYL)-ACETAMIDINE | | Synonyms: | N-(5-AMINO-5-CARBOXYPENTYL)-ACETAMIDINE;N-EPSILON-ACETIMIDOYL-L-LYSINE;N-EPSILON-ACETIMIDOYL-L-LYSIN-EPSILON;H-LYS(1-IMINOETHYL)-OH;H-LYS(ACETIMIDOYL)-OH;LYSINE(ACETIMIDOYL)-OH;N-(5-Amino-5-carboxypentyl;Ne-Acetimidoyl-L-lysine | | CAS: | 53774-63-3 | | MF: | C8H17N3O2 | | MW: | 187.24 | | EINECS: | | | Product Categories: | | | Mol File: | 53774-63-3.mol |  |
| | N-(5-AMINO-5-CARBOXYPENTYL)-ACETAMIDINE Chemical Properties |
| Boiling point | 335.2±52.0 °C(Predicted) | | density | 1.22±0.1 g/cm3(Predicted) | | storage temp. | -15°C | | solubility | Water: 50 mg/mL (267.04 mM); DMSO: < 1 mg/mL (insoluble or slightly soluble) | | pka | 2.52±0.24(Predicted) | | form | Solid | | color | White to off-white |
| | N-(5-AMINO-5-CARBOXYPENTYL)-ACETAMIDINE Usage And Synthesis |
| Uses | L-NIL is an inducible NO synthase inhibitor, with an IC50 of 3.3 μM for miNOS[1][2][3]. | | Biological Activity | L-NIL is an inhibitor of inducible nitric oxide synthase (iNOS) with an IC50 value of 3.3 μM for miNOS. | | in vitro | L-NIL produces a concentration-dependent inhibition of both the mouse inducible NOS (miNOS) and the rat brain constitutive NOS (rcNOS) and is considerably more potent for miNOS. The IC 50 values for L-NIL with miNOS and rcNOS are 3.3 and 92 pM, respectively, indicating that it is 28-fold more selective for miNOS. In addition, L-NIL has approximately 6-fold greater potency for miNOS than either L -NMA or L-NNA. | | in vivo | L-NIL (10 and 30 mg/kg, IP) prevents the inflammation, oxidative stress and autophagy induced by renal IR in mice[1]. | Animal Model: | Adult male Balb/c (20-25 g)[1]. | | Dosage: | 10 and 30mg/kg. | | Administration: | Intraperitoneally at the end of CLP and at 6h after sepsis induction. | | Result: | Led to a negligible increase in plasma NGAL compared to sham mice.
Led to a significant decrease in both TLR4 and IL1β protein contents and clusterin transcript.
Showed an increase in NFAT5 mRNA levels, as compared with mice treated with vehicle.
Promoted a decrease in AR protein expression, as compared with animals treated with vehicle.
|
| | target | IC50: 3.3 μM (mouse inducible NO synthase), 92 μM (rat brain constitutive NO synthase) | | IC 50 | iNOS | | References | [1] Consuelo Pasten, et al. l-NIL prevents the ischemia and reperfusion injury involving TLR-4, GST, clusterin, and NFAT-5 in mice. Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F624-F634. DOI:10.1152/ajprenal.00398.2018
[2] Sharon Angela Tanuseputero, et al. Intravenous Arginine Administration Downregulates NLRP3 Inflammasome Activity and Attenuates Acute Kidney Injury in Mice with Polymicrobial Sepsis. Mediators Inflamm. 2020 May 11;2020:3201635. DOI:10.1155/2020/3201635
[3] Moore WM, et al. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem. 1994 Nov 11;37(23):3886-8. DOI:10.1021/jm00049a007 |
| | N-(5-AMINO-5-CARBOXYPENTYL)-ACETAMIDINE Preparation Products And Raw materials |
|